Drugs for Lingual-Facial-Buccal Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 184)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Zonisamide |
Approved, Investigational |
Phase 4 |
|
68291-97-4 |
5734 |
Synonyms:
1-(1,2-benzisoxazol-3-yl)methanesulfonamide
1-(1,2-Benzoxazol-3-Yl)methanesulfonamide
1,2-Benzisoxazole-3-methanesulfonamide
1,2-Benzisoxazole-3-methanesulphonamide
1,2-benzoxazol-3-ylmethanesulfonamide
3-(Sulfamoylmethyl)-1,2-benzisoxazole
3-(Sulphamoylmethyl)-1,2-benzisoxazole
3-sulfamoylmethyl-1,2-benzisoxazole
3-Sulfamoylmethyl-1,2-benzisoxazole
68291-97-4
AC-1413
AC1L1L0Q
AC1Q55GQ
AD 810
AD-810
AD-810N
AKOS001312269
benzo[D]Isoxazol-3-yl-methanesulfonamide
Benzo[d]isoxazol-3-yl-methanesulfonamide
benzo[D]Isoxazol-3-yl-methanesulphonamide
BIDD:GT0708
BIDD:PXR0183
Bio-0532
BRD-K48300629-001-03-8
BRN 1077076
C022189
C07504
C8H8N2O3S
CHEBI:10127
CHEMBL750
CI 912
CI-912
CID5734
CPD000596519
D00538
DB00909
E-2090
Elan brand of zonisamide
Elan brand OF zonisamide
|
Exceglan
Excegram
Excegran
Excegran (TN)
FT-0082702
HMS2089O07
HSDB 7293
I06-0495
LS-33637
MLS001195632
MLS001306491
MolPort-002-507-855
NCGC00159319-02
NCGC00159319-03
PD 110843
PD-110843
S1445_Selleck
SAM002548957
SMR000596519
SPR_2
STK711131
Tremode
Trerief
UNII-459384H98V
ZINC00004321
Zonegran
Zonegran, Zonisamide
Zonisamida
Zonisamida [Spanish]
zonisamide
Zonisamide
Zonisamide (JAN/USAN/INN)
Zonisamide (ZNS)
Zonisamide [USAN:BAN:INN:JAN]
zonisamide monosodium
Zonisamide monosodium
Zonisamidum
Zonisamidum [Latin]
|
|
2 |
|
Aripiprazole |
Approved, Investigational |
Phase 4 |
|
129722-12-9 |
60795 |
Synonyms:
||OPC 14597
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
aripiprazol
Aripiprazol
aripiprazole
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
aripiprazolum
Aripiprazolum
Aripirazole
Arpizol
Asprito|
Bio-0004
BMS-337039
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
|
CHEMBL1112
CID60795
CPD000466383
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
Opc 14597
OPC 31
OPC-14597
OPC-31
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
|
|
3 |
|
Levetiracetam |
Approved |
Phase 4 |
|
102767-28-2 |
441341 |
Synonyms:
(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
102767-28-2
AC-1479
AC1NR4PY
alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
BIDD:GT0242
C8H14N2O2
CHEMBL1286
CID5284583
CPD000466303
e Keppra
Etiracetam
Etiracetam levo-isomer
Etiracetam, R-isomer
etiracetam, S-isomer
Etiracetam, S-isomer
FT-0082600
HMS2051D07
HMS2089L20
Keppra
Keppra XR
Keppra, Keppra XR),Levetiracetam
L-059
levetiracetam
Levetiracetam
Levetiracetam [INN]
|
Levetiracetame
Levetiracetamum
Levetiracetamum [INN-Latin]
Levetiractam
Leviteracetam
Levitiracetam
LS-137054
MLS000759403
MLS001424069
MolPort-003-848-377
NCGC00186028-01
S1356_Selleck
SAM001246539
SBB070161
SIB-S1
SMR000466303
TL8000131
Torleva
UCB brand OF levetiracetam
Ucb L059
ucb L060
Ucb L060
UCB-22059
UCB-L 059
Ucb-L059
UCB-L059
Ucb-L060
ZINC01547851
|
|
4 |
|
tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
5 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
94-09-7, 1994-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
|
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
6 |
|
Amantadine |
Approved |
Phase 4 |
|
768-94-5 |
2130 |
Synonyms:
1 Aminoadamantane
138576_ALDRICH
1-Adamantamine
1-adamantanamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-adamantylamine
1-Adamantylamine
1-aminoadamantane
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
665-66-7 (hydrochloride)
768-94-5
AB00514655
AbZ brand OF amantadine hydrochloride
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
Adamantamine
adamantan-1-amine
adamantan-1-ylamine
Adamantanamine
ADAMANTANE,1-AMINO
Adamantylamine
Adekin
AKOS000113994
AKOS000119324
AL, amantadin
Aliud brand OF amantadine sulfate
Alliance brand OF amantadine hydrochloride
Aman
Amant
Amanta
Amanta hci azu
Amanta sulfate azu
Amantadin al
Amantadin azu
Amantadin neuraxpharm
Amantadin ratiopharm
Amantadin stada
Amantadina
Amantadina [INN-Spanish]
Amantadina juventus
Amantadina llorente
amantadine
Amantadine
Amantadine (INN)
Amantadine [INN:BAN]
Amantadine base
Amantadine Base
Amantadine HCL
amantadine hydrochloride
Amantadine hydrochloride
Amantadine sulfate
Amantadinneuraxpharm
Amantadin-neuraxpharm
Amantadinratiopharm
Amantadin-ratiopharm
Amantadinum
Amantadinum [INN-Latin]
Amanta-hci-azu
AmantaHCIAZU
Amantasulfateazu
Amanta-sulfate-azu
Amantidine
Ambap768-94-5
Aminoadamantane
Amixx
AZU, amantadin
Azupharma brand OF amantadine hydrochloride
Azupharma brand OF amantadine sulfate
BIA4304
BIDD:GT0757
Bio-0821
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
C06818
C10H17N
Cerebramed
CHEBI:2618
CHEMBL660
Ciba geigy brand OF amantadine hydrochloride
Ciba-geigy brand OF amantadine hydrochloride
CID2130
D07441
DB00915
Desitin brand OF amantadine hydrochloride
DivK1c_000815
Du pont brand OF amantadine hydrochloride
EINECS 212-201-2
Endantadine
endo Brand OF amantadine hydrochloride
Gen amantadine
Gen-amantadine
GenAmantadine
Gen-Amantadine
Genpharm brand OF amantadine hydrochloride
Hexal brand OF amantadine sulfate
|
HMS1791O12
HMS1989O12
Hormosan brand OF amantadine sulfate
HSDB 3202
Hydrochloride, amantadine
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
infecto Flu
infecto-Flu
InfectoFlu
Infectopharm brand OF amantadine hydrochloride
Infex
Juventus brand OF amantadine hydrochloride
Juventus, amantadina
KBio1_000815
KBio2_000390
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
Krewel brand OF amantadine hydrochloride
L000868
Llorente brand OF amantadine hydrochloride
Llorente, amantadina
Lopac0_000004
Lopac-A-1260
LS-157049
Mantadine
Mantadix
Merz brand OF amantadine sulfate
Midantan
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
Neuraxpharm brand OF amantadine sulfate
neuro Hexal brand OF amantadine sulfate
NINDS_000815
Novartis brand OF amantadine hydrochloride
NSC 341865
NSC341865
NSC83653
Oprea1_248648
OR14310
Orion brand OF amantadine hydrochloride
Pharmascience brand OF amantadine hydrochloride
Pk-merz
Pk-Merz
PMS Amantadine
PMSAmantadine
PMS-Amantadine
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
Ratiopharm brand OF amantadine hydrochloride
Solvay brand OF amantadine hydrochloride
SPBio_000002
SPBio_002273
Spectrum_000030
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Stada brand OF amantadine hydrochloride
Stada brand OF amantadine sulfate
Stada, amantadin
STK298781
Sulfate, amantadine
Symadine
Symmetrel
TCMDC-125869
Thiemann brand OF amantadine hydrochloride
TL8005280
Tregor
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
tricyclo[3.3.1.1(3,7)]Decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]Decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1(3,7)]Decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
Wiregyt
WLN: L66 B6 A B- C 1B ITJ BZ
|
|
7 |
|
Risperidone |
Approved, Investigational |
Phase 4 |
|
106266-06-2 |
5073 |
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
Belivon
BIDD:GT0262
Bio-0092
BRD-K53857191-001-04-5
BRN 4891881
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
Consta, risperdal
Consta, Risperdal
CPD000466323
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
Lopac-R-118
LS-134196
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
NCGC00015883-02
|
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R64,766
R-64,766
R64766
R-64766
R-64-766
Rispen
Risperdal
Risperdal (TN)
Risperdal consta
Risperdal Consta
Risperdal m-tab
Risperdal M-Tab
risperdone
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
risperidone
Risperidone
Rispéridone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
Sequinan
SMR000466323
SPBio_003078
Spiron
STK646402
TL8000230
UNII-L6UH7ZF8HC
|
|
8 |
|
Olanzapine |
Approved, Investigational |
Phase 4 |
|
132539-06-1 |
4585 |
Synonyms:
132539-06-1
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC1L1IHS
AC-665
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
Lanzac
Lilly brand of olanzapine
LS-152313
LY 170053
LY-170052
|
LY-170053
Midax
MLS000759457
MLS001165781
MLS001195646
MLS001424057
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
olanzapina
Olanzapina
olanzapine
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
olanzapinum
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa intramuscular
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa zydis
Zyprexa Zydis
|
|
9 |
|
Amisulpride |
Approved, Investigational |
Phase 4 |
|
53583-79-2, 71675-85-9 |
2159 |
Synonyms:
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid
4-amino-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
4-amino-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide
4-amino-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulphonyl)-2-methoxybenzamide
4-amino-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulphonyl)-O-anisamide
4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide
4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide
4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
71675-85-9
A2729_SIGMA
AC1L1D1X
AC-6820
Aminosultopride
Amisulpiride
Amisulprida
Amisulprida [INN-Spanish]
amisulpride
Amisulpride
Amisulpride (INN)
Amisulpride [INN]
Amisulpridum
Amisulpridum [INN-Latin]
Barnetil
Bio-0114
BRD-A60197193-001-05-4
C17H27N3O4S
CHEMBL243712
CID2159
CPD000449309
D07310
|
DAN 2163
DAN-2163
DB06288
Deniban
Deniban (TN)
EINECS 275-831-7
HMS2051K10
I06-0334
L000106
LS-25532
MLS000758258
MLS000759450
MLS001424039
MolPort-003-983-463
N-(Ethyl-1-pyrrolidinyl- 2-methyl)methoxy-2-ethylsulfonyl-5-benzamide
NCGC00092310-01
NCGC00092310-02
NCGC00092310-04
S1280_Selleck
SAM001246639
SAM001246966
SL-91.1077
SMR000449309
Socian
Solian
Solian (TN)
Solian, Amisulpride
STK635172
Sultopride
Sultopride hydrochloride
Sultopridum
Sultroprida
|
|
10 |
|
Galantamine |
Approved |
Phase 4 |
|
357-70-0 |
9651 |
Synonyms:
(-)-Galanthamine
(-)-GALANTHAMINE
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
1551-02-6
1953-04-4
1dx6
1qti
357-70-0
4-27-00-02184 (Beilstein Handbook Reference)
736-79-8
AC1L1TIM
AC-20240
BIDD:GT0517
BPBio1_000480
BRD-K49481516-004-03-5
BRD-K49481516-004-04-3
BRN 0093736
BSPBio_000436
BSPBio_003416
C08526
CHEBI:42944
CHEMBL659
CID9651
D04292
DivK1c_000590
Galantamin
Galantamina
Galantamina [INN-Spanish]
Galantamine
Galantamine (USAN/INN)
Galantamine [USAN:INN]
Galantaminum
Galantaminum [INN-Latin]
galanthamine
Galanthamine
Galanthamine hydrobromide
Galanthaminum
GNT
HMS2089H03
HSDB 7361
|
IDI1_000590
InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
Jilkon
KBio1_000590
KBio2_001751
KBio2_004319
KBio2_006887
KBio3_002636
KBioGR_001417
KBioSS_001751
LS-71039
Lycoremin
Lycoremine
MolPort-002-521-885
NCGC00024731-02
NINDS_000590
Nivalin
Nivaline
NSC 100058
ortho McNeil neurologics brand OF galantamine
ortho-McNeil neurologics brand OF galantamine
Prestwick0_000588
Prestwick1_000588
Prestwick2_000588
Prestwick3_000588
Probes1_000055
Probes2_000395
Razadyne
Razadyne ER
Reminyl
Reminyl (TN)
SDCCGMLS-0066737.P001
SMP1_000131
SPBio_002655
Spectrum_001271
Spectrum3_001738
Spectrum4_000839
Spectrum5_001673
STOCK1N-46108
UNII-0D3Q044KCA
|
|
11 |
|
Clozapine |
Approved |
Phase 4 |
|
5786-21-0 |
2818 |
Synonyms:
3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine
5786-21-0
8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine
8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine
8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine
8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine
8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
AC1L1EJE
AC1Q3OPZ
AC1Q3ZWP
AC-280
AKOS005064444
AR-1I2412
Asaleptin
Bio1_000436
Bio1_000925
Bio1_001414
Bio2_000310
Bio2_000790
BRD-K37289225-001-09-1
BRN 0764984
C 6305
C06924
C18H19ClN4
C6305_SIGMA
CAS-5786-21-0
CCRIS 9171
CHEBI:3766
CHEMBL42
CID2818
Clorazil
Clozapin
Clozapina
Clozapina [INN-Spanish]
clozapine
Clozapine
Clozapine (JAN/USP/INN)
Clozapine [USAN:INN:BAN]
clozapine(tautomer)
Clozapinum
Clozapinum [INN-Latin]
Clozaril
CLOZARIL
Clozaril (TN)
CPD000058365
D00283
D003024
DB00363
DivK1c_000343
EINECS 227-313-7
EU-0100276
Fazaclo
Fazaclo ODT
FT-0082373
HF1854
HF-1854
HMS1361P12
HMS1569E21
HMS1791P12
HMS1921C16
HMS1989P12
HMS2089L13
HMS2092I16
|
HMS501B05
HSDB 6478
I06-0047
InChI=1/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
Iprox
KBio1_000343
KBio2_000310
KBio2_000599
KBio2_002878
KBio2_003167
KBio2_005446
KBio2_005735
KBio3_000619
KBio3_000620
KBio3_002979
KBioGR_000310
KBioGR_001336
KBioSS_000310
KBioSS_000599
KS-1166
L000195
L013417
Leponex
Lepotex
LEX-123
Lopac-C-6305
LS-60881
LX 100-129
MLS000028472
MLS001077282
MolPort-001-728-041
NCGC00015254-01
NCGC00015254-02
NCGC00015254-03
NCGC00015254-07
NCGC00015254-17
NCGC00022902-02
NCGC00022902-04
NCGC00022902-05
NCGC00022902-06
NCGC00022902-07
NCGC00022902-08
NCGC00022902-09
NCGC00022902-10
NCGC00022902-11
NCGC00022902-13
NINDS_000343
Prestwick_693
Prestwick0_000350
Prestwick1_000350
S2459_Selleck
SAM002548976
SMR000058365
SPBio_000798
SPBio_002340
Spectrum_000139
SPECTRUM1500685
Spectrum2_000919
Spectrum3_001828
Spectrum4_000898
Tocris-0444
UNII-J60AR2IKIC
W-801
|
|
12 |
|
Prednisone |
Approved, Vet_approved |
Phase 4 |
|
53-03-2 |
5865 |
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
Acis brand OF prednisone
ACon0_000082
ACon1_000297
Adasone
AI3-52939
Ancortone
apo-Prednisone
Apo-prednisone
Apo-Prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Bio-0649
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
C07370
C21H26O5
Cartancyl
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
CPD001227202
Cutason
Dacorten
Dacortin
DB00635
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
delta cortelan
Delta Cortelan
Delta E
Delta E.
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
Delta-cortelan
Delta-Cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Delta-cortisone
delta-Cortone
Deltacortone
Delta-cortone
Delta-dome
Delta-Dome
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
EINECS 200-160-3
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
Fernisone
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
HMS1568O15
HMS2090J13
|
Hoechst brand OF prednisone
Hostacortin
HSDB 3168
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
Liquid pred
Liquid Pred
Lisacort
LMST02030180
Lodotra
LS-1325
MEGxm0_000443
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
Mibe brand OF prednisone
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI60_000008
NCI-C04897
Nisona
Nizon
Novoprednisone
NSC 10023
NSC10023
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
Predni tablinen
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone [INN:BAN]
Prednisone Intensol
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick_405
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
Servisone
SK-Prednisone
SMR000718760
SMR001227202
Solvay brand OF prednisone
Sone
SPBio_002214
Sterapred
Supercortil
Trommsdorff brand OF prednisone
U 6020
Ultracorten
Ultracortene
UNII-VB0R961HZT
Winpred
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Wojtab
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
ZINC03875357
|
|
13 |
|
chloroquine |
Approved, Investigational, Vet_approved |
Phase 4 |
|
54-05-7 |
2719 |
Synonyms:
( -)-Chloroquine
(-)-Chloroquine
(+)-Chloroquine
(R)-(-)-Chloroquine
{4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine
3377 RP opalate
3545-67-3
50-63-5
54-05-7
56598-66-4
58175-86-3
58175-87-4
7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline
7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline
AB00053436
AC1L1EB8
AC1Q2ZA7
AC1Q2ZA8
Amokin
Aralen
Aralen HCl
Arechin
Arechine
Arequin
Arolen
Arthrochin
Artrichin
Avlochlor
Avloclor
Bemaco
Bemaphate
Bemaphic acid
Bemasulph
Benaquin
Bipiquin
BPBio1_000655
BRD-A91699651-065-01-1
BRN 0482809
BSPBio_000595
BSPBio_002001
C07625
C18H26ClN3
Capquin
CCRIS 3439
CHEBI:3638
CHEMBL76
Chemochin
Chingamin
Chloraquine
Chlorochin
Chlorochine
Chlorochinum
Chloroin
Chloroquin
Chloroquina
chloroquine
Chloroquine
Chloroquine (USP/INN)
Chloroquine (VAN)
Chloroquine [USAN:INN:BAN]
Chloroquine Bis-Phosphoric Acid
Chloroquine phosphate
Chloroquine Phosphate
Chloroquine sulfate
Chloroquine sulphate
Chloroquinium
Chloroquinum
Chloroquinum [INN-Latin]
Chlorquin
CID2719
Cidanchin
Clorochina
Clorochina [DCIT]
Cloroquina
Cloroquina [INN-Spanish]
Cocartrit
CQ
CU-01000012392-2
D02366
Dawaquin
DB00608
Delagil
Dichinalex
DivK1c_000404
EINECS 200-191-2
Elestol
Gontochin
Gontochin phosphate
Heliopar
HMS2090O03
HSDB 3029
Hydroxychloroquine Sulfate
IDI1_000404
Imagon
|
Ipsen 225
Iroquine
KBio1_000404
KBio2_000592
KBio2_003160
KBio2_005728
KBio3_001221
KBioGR_000778
KBioSS_000592
Khingamin
Klorokin
Lapaquin
Lopac0_000296
LS-141726
Malaquin
Malaquin (*Diphosphate*)
Malaren
Malarex
Mesylith
Miniquine
MolMap_000009
MolPort-001-783-623
N(4)-(7-chloro-4-Quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine
NCGC00015256-04
NCGC00162120-01
nchembio.215-comp4
nchembio.368-comp8
nchembio.87-comp17
NCI60_000894
Neochin
NINDS_000404
Nivachine
Nivaquine
Nivaquine b
Nivaquine B
NSC 187208
NSC14050
NSC187208
Pfizerquine
Plaquenil
Prestwick0_000548
Prestwick1_000548
Prestwick2_000548
Prestwick3_000548
Quinachlor
Quinagamin
Quinagamine
Quinercyl
Quingamine
Quinilon
Quinoscan
Resochen
Resochin
Resoquina
Resoquine
Reumachlor
Reumaquin
Rivoquine
Ro 01-6014/N2
Ronaquine
Roquine
RP 3377
RP-3377
Sanoquin
Silbesan
Siragan
SMP2_000034
SN 6718
SN-7618
Solprina
Sopaquin
SPBio_000174
SPBio_002516
Spectrum_000132
Spectrum2_000127
Spectrum3_000341
Spectrum4_000279
Spectrum5_000707
ST 21
ST 21 (pharmaceutical)
Sulfate, chloroquine
Sulphate, chloroquine
Tanakan
Tanakene
Tresochin
Trochin
UNII-886U3H6UFF
W 7618
WIN 244
WLN: T66 BNJ EMY1&3N2&2 IG
|
|
14 |
|
Azathioprine |
Approved |
Phase 4 |
|
446-86-6 |
2265 |
Synonyms:
[Methyl(nitroimidazolyl)mercaptopurine]
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC1L1DAL
AC1Q3Z1F
AC-4230
AI3-50290
AI-981/34845012
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
azathioprine
Azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprine Sodium
Azathioprine sodium salt
Azathioprine sulfate
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
azatiopr in
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57322
BW 57-322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
Ccucol
CHEBI:2948
CHEMBL1542
ChemDiv1_002659
CID2265
cMAP_000046
CPD000427366
Cytostatics
D00238
DB00993
DivK1c_000586
|
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
Lopac0_000027
Lopac-A-4638
LS-123
Methylnitroimidazolylmercaptopurine
MLS001049307
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC39084
NSC-39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick_41
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
Sodium, azathioprine
SPBio_000255
SPBio_001987
Spectrum_000064
SPECTRUM1500133
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
STK831906
STOCK1S-20293
STOCK1S-27186
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
|
|
15 |
|
Varenicline |
Approved, Investigational |
Phase 4 |
|
249296-44-4 |
5310966 |
Synonyms:
249296-44-4
6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-H)Benzazepine
7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino(2,3-H)(3)Benzazepine
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine
7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline
AC1L55H0
AC1Q4W6H
AKOS005145561
AR-1H2911
Champix
Chantix
CHEBI:430452
CHEMBL1396
CID170361
|
CP 526555
CP-526,555
D08669
HSDB 7591
I14-1963
LS-187375
Tartrate, varenicline
UNII-W6HS99O8ZO
Vareniclina
varenicline
Varenicline
Varenicline (INN)
Varenicline tartrate
Vareniclinum
|
|
16 |
|
Acetylcholine |
Approved, Investigational |
Phase 4 |
|
51-84-3 |
187 |
Synonyms:
2-(Acetyloxy)-N,N,N-trimethylethanaminium
Acetilcolina cusi
Acetyl choline ion
Acetylcholine bromide
Acetylcholine cation
acetylcholine chloride
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
Acetylcholinium: acetyl-choline
ACh
Alcon brand OF acetylcholine chloride
|
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
17 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
18 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
19 |
|
Serotonin Receptor Agonists |
|
Phase 4 |
|
|
|
20 |
|
Serotonin 5-HT1 Receptor Agonists |
|
Phase 4 |
|
|
|
21 |
|
Hormones |
|
Phase 4 |
|
|
|
22 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
23 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
24 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
25 |
|
Analgesics |
|
Phase 4 |
|
|
|
26 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
27 |
|
Antiprotozoal Agents |
|
Phase 4 |
|
|
|
28 |
|
Antiparasitic Agents |
|
Phase 4 |
|
|
|
29 |
|
Antimalarials |
|
Phase 4 |
|
|
|
30 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
31 |
|
Dopamine Antagonists |
|
Phase 4 |
|
|
|
32 |
|
Antiemetics |
|
Phase 4 |
|
|
|
33 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
34 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
35 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
36 |
|
Serotonin Uptake Inhibitors |
|
Phase 4 |
|
|
|
37 |
|
Cholinesterase Inhibitors |
|
Phase 4 |
|
|
|
38 |
|
Paliperidone Palmitate |
|
Phase 4 |
|
|
|
39 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
40 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
41 |
|
Anthelmintics |
|
Phase 4 |
|
|
|
42 |
|
Amebicides |
|
Phase 4 |
|
|
|
43 |
|
Chloroquine diphosphate |
|
Phase 4 |
|
50-63-5 |
|
44 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
45 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
46 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
47 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
48 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
49 |
|
Antipsychotic Agents |
|
Phase 4 |
|
|
|
50 |
|
Aromatic Amino Acid Decarboxylase Inhibitors |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 256)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease |
Unknown status |
NCT03034538 |
Phase 4 |
Zonegran;Zonegran |
2 |
Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study |
Unknown status |
NCT00837707 |
Phase 4 |
aripiprazole |
3 |
A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study |
Unknown status |
NCT02472210 |
Phase 4 |
Botulinum Toxin |
4 |
The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial |
Unknown status |
NCT00468533 |
Phase 4 |
Aripiprazole |
5 |
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics |
Completed |
NCT00888186 |
Phase 4 |
levodopa/carbidopa |
6 |
Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study |
Completed |
NCT00307450 |
Phase 4 |
Levetiracetam |
7 |
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine |
Completed |
NCT03698331 |
Phase 4 |
Valbenazine;Placebo oral capsule |
8 |
Validation of Dyskinesia Rating Scales |
Completed |
NCT01071395 |
Phase 4 |
Amantadine;Placebo |
9 |
D-serine Adjuvant Treatment for Parkinson's Disease |
Completed |
NCT00215904 |
Phase 4 |
D-serine (~2g/day) |
10 |
A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia |
Completed |
NCT00621998 |
Phase 4 |
risperidone;olanzapine |
11 |
Tardive Dyskinesia and Cognitive Function |
Completed |
NCT00926965 |
Phase 4 |
amisulpride;Olanzapine;Conventional antipsychotics |
12 |
Treatment of Tardive Dyskinesia With Galantamine |
Completed |
NCT00164242 |
Phase 4 |
Galantamine |
13 |
Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK. |
Completed |
NCT00632762 |
Phase 4 |
mantadix |
14 |
The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia |
Completed |
NCT00950196 |
Phase 4 |
amantadine sulphate |
15 |
Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study |
Completed |
NCT01279213 |
Phase 4 |
paliperidone clozapine |
16 |
Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial |
Completed |
NCT02463331 |
Phase 4 |
Chloroquine diphosphate;prednisone;azathioprine |
17 |
DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS |
Completed |
NCT01980745 |
Phase 4 |
Chloroquine diphosphate 250mg;Placebo |
18 |
A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia |
Completed |
NCT00114595 |
Phase 4 |
eicosapentaenoic acid |
19 |
A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia |
Recruiting |
NCT03891862 |
Phase 4 |
Valbenazine;Placebo oral capsule |
20 |
Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation |
Recruiting |
NCT02480803 |
Phase 4 |
Continuous intrajejunal infusion of levodopa-carbidopa |
21 |
Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response |
Recruiting |
NCT03495024 |
Phase 4 |
Varenicline |
22 |
The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study) |
Active, not recruiting |
NCT00354133 |
Phase 4 |
Best Medical Treatment |
23 |
Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study |
Terminated |
NCT00477802 |
Phase 4 |
|
24 |
Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial |
Unknown status |
NCT02617017 |
Phase 3 |
Buspirone;Placebo |
25 |
Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease |
Unknown status |
NCT00260793 |
Phase 3 |
Ropinirole Hydrochloride |
26 |
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) |
Unknown status |
NCT02202551 |
Phase 3 |
ADS-5102 |
27 |
Levetiracetam Treatment of Tardive Dyskinesia |
Completed |
NCT00291213 |
Phase 3 |
levetiracetam;placebo |
28 |
A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia |
Completed |
NCT02195700 |
Phase 2, Phase 3 |
SD-809;Placebo |
29 |
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia |
Completed |
NCT02291861 |
Phase 3 |
SD-809;Placebo |
30 |
A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia |
Completed |
NCT02405091 |
Phase 3 |
NBI-98854 |
31 |
A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects. |
Completed |
NCT00363727 |
Phase 3 |
ropinirole controlled-release (REQUIP CR) for RLS |
32 |
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia |
Completed |
NCT00105521 |
Phase 3 |
Sarizotan;Placebo |
33 |
A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia |
Completed |
NCT00105508 |
Phase 3 |
Sarizotan;Placebo |
34 |
Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects |
Completed |
NCT00360568 |
Phase 3 |
Levodopa-carbidopa intestinal gel |
35 |
Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia |
Completed |
NCT02736955 |
Phase 3 |
Valbenazine |
36 |
A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia |
Completed |
NCT00672373 |
Phase 3 |
Extract of Ginkgo Biloba (EGb-761 capsules);Placebo |
37 |
An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication) |
Completed |
NCT02799381 |
Phase 3 |
ABT-SLV187;optimized antiparkinsonian treatment |
38 |
Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy |
Completed |
NCT00408915 |
Phase 3 |
Continuous Subcutaneous Lisuride Infusion |
39 |
Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease |
Completed |
NCT00180037 |
Phase 3 |
Coenzyme Q10 Nanodispersion (Nanoquinone);Placebo |
40 |
A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy. |
Completed |
NCT00199394 |
Phase 3 |
Istradefylline (KW-6002) |
41 |
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) |
Completed |
NCT01397422 |
Phase 2, Phase 3 |
ADS-5102 (extended release amantadine HCl) |
42 |
Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) |
Completed |
NCT02136914 |
Phase 3 |
ADS-5102 |
43 |
ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study) |
Completed |
NCT02274766 |
Phase 3 |
ADS-5102 |
44 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia |
Completed |
NCT02274558 |
Phase 3 |
NBI-98854;Placebo |
45 |
Deep Brain Stimulation for Parkinson's Disease Trial |
Completed |
NCT00053625 |
Phase 3 |
|
46 |
A 6-Month, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5 - 12 mg/Day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia |
Completed |
NCT00488319 |
Phase 3 |
Paliperidone ER |
47 |
Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial |
Completed |
NCT01543321 |
Phase 3 |
Tetrabenazine;Placebo |
48 |
Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study |
Completed |
NCT00190008 |
Phase 3 |
piracetam |
49 |
Effect of Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics |
Recruiting |
NCT03790345 |
Phase 2, Phase 3 |
Pyridoxine;Cobalamin;Placebo Oral Tablet |
50 |
Long Term Aerobic Exercise to Slow Progression in Parkinson's Disease |
Recruiting |
NCT03808675 |
Phase 2, Phase 3 |
|
Cochrane evidence based reviews: dyskinesias
|